Cas:313701-78-9 3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid manufacturer & supplier

Chemical Name:3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid

CAS.NO:313701-78-9

Synonyms:3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid

Molecular Formula:C₁₄H₁₅NO₂

Molecular Weight:229.27400

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:422ºC at 760 mmHg

Density:1.12g/cm3

Index of Refraction:1.572

PSA:42.23000

Exact Mass:229.11000

LogP:3.10070

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid Use and application,3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid technical grade,usp/ep/jp grade.

Related News: The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid manufacturer Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added. 3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid supplier Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday. 3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid vendor The company memo said Lilly couldn’t substantiate allegations that employees faced retaliation for refusing to make false statements. It did not address employees’ specific complaints that they faced retaliation for other reasons, other than to say it encouraged employees to “speak up.” 3-(2,5-dimethylpyrrol-1-yl)-4-methylbenzoic acid factory The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting.